November 20, 2019 by BioHouston LivaNova to Restructure its Heart Valve Business Line and End Caisson Transcatheter Mitral Valve Replacement Program
November 8, 2019 by BioHouston Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC
November 6, 2019 by BioHouston Saranas Announces First Commercial Case With Early Bird® Bleed Monitoring System in the U.S.
November 5, 2019 by BioHouston Fannin Awarded $2,000,000 NIH Grant For Continued Development of Fetal Surgery Device
October 28, 2019 by BioHouston Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement